Jointly organised by the BSAC and GARDP. For 2021, the conference collaborators were the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), the German Center for Infection Research (DZIF) and the International Research Alliance for Antibiotic Discovery and Development (IRAADD) (a JPIAMR funded network)
Programme
SESSION ONE: KEYNOTE PRESENTATION
Chair: Professor Laura JV Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP) - View Bio
-
View Session One here. This video consists of the following presentations:
1300
Introductory remarks
Professor Laura JV Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP) - View Bio
1305
The politics of drug development
Dame Sally Davies, UK Government Special Envoy on Antimicrobial Resistance, UK Department of Health and Social Care - View Bio
1325
Q&A
SESSION TWO: Early Drug Discovery
Chair: Dr Marcus Miethke, Scientist & Project Manager, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) - View Bio
-
View Session Two here. This video consists of the following presentations:
1345
In vitro and in vivo profiling of natural products from Myxobacteria towards the development of anti-infective drugs
Dr Jennifer Herrmann, Scientist, HIPS/HZI & DZIF - View Bio
1400
Gram-negative antibacterial discovery - looking for the high-hanging fruits
Dr Benjamin Blasco Discovery Senior Project Manager, GARDP - View Bio
1415
Microbial natural products: still an untapped source for novel antibiotic discovery
Dr Olga Genilloud, Scientific Director, Fundación MEDINA - View Bio
1430
Q&A
All speakers
SESSION THREE: Pre-clinical antimicrobial development
Chair: Professor Alasdair MacGowan, Consultant in Infection at North Bristol NHS Trust & Professor of Antimicrobial Therapeutics at the University of Bristol - View Bio
-
View Session Three here. This video consists of the following presentations:
1450
From old drugs to new: Repurposing old antibiotics to combat antimicrobial resistance
Dr Christopher Darlow, MRC Clinical Research Fellow, Institute of Systems, Molecular & Integrative Biology, University of Liverpool - View Bio
1505
Linking PK and PD studies in animals with PBPK/PD modelling – in silico from mouse to human
Dr Katharina Rox, Postdoc, HZI/DZIF - View Bio
1520
Pre-clinical development of Corallopyronin A – a novel natural product active against helminths, STIs and Staphylococci
Professor Achim Hoerauf, Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn/DZIF - View Bio
1535
Q&A
All speakers
SESSION FOUR: POSTER SESSION
Chair: Prof Dr Rolf Müller, Head of Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) & Department Microbial Natural Products (MINS), Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) - View Bio
-
View Session Four here. This video consists of the following presentations:
1555
Clinical outcomes in Carbapenem resistant Enterobacteriaceae infections treated with Ceftazidime-avibactam: A single centre observational study
Balram Rathish, Clinical Fellow in Infectious Diseases, Aster Medcity, Kochi, India
1558
5-Fluorouracil – mechanism of action and resistance mechanisms
Sara Henderson , Research associate, Norwich Medical School, UEA, UK
1601
Worse than a stroke? Long-term outcome and risk factors for late mortality in Gram-negative bacteraemia
Ioannis Baltas, Foundation Year 3 Doctor, Frimley Health NHS Foundation Trust, UK
1604
Genomic and Bioassay-guided Approaches for Discovery of Novel Antibiotics from Marine Bacteria
Matthias Agbo, University of Nigeria, Nsukka
1607
Epigenetic Mode of Bacterial Drug Resistance
Guru Prasad Manderwad, Kamineni Academy of Medical Sciences and Research Centre
1610
Ecm16 protein confers resistance against the DNA intercalator antibiotic echinomycin
Priyanka Gade, University of Texas at El Paso
1613
Genomic analysis of Colistin resistance in Carbapenem-Resistant Enterobacterales and XDR Klebsiella pneumoniae
Raunak Bir, Senior Resident Doctor, All India Institute of Medical Sciences, New Delhi, India
1616
Formulation, Characterization and Evaluation of Wog19-Loaded and Wog19 +Chloroquine-Loaded Solid Lipid Nanoparticles for the Treatment of Malaria Caused by Sensitive and Resistant Strains of P. berghei
Samuel Uzondu, Lecturer /Researcher, NanoMalaria Research Unit, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka
1619
The Three Ages of Antibiotics
Emily Mayhew, Historian in residence, Dept of Bioengineering, Imperial College London
1621
Q&A
1630
Day one closing remarks
Professor William Hope, University of Liverpool - View Bio
SESSION FIVE: Learning lessons: clinical trials
Chair: Professor Mike Sharland, Consultant in paediatric infectious diseases, St George's University Hospitals NHS Foundation Trust - View Bio
-
View Session Five here. This video consists of the following presentations:
1300
Introductory remarks
Professor William Hope, University of Liverpool - View Bio
1305
Lessons for Clinical Research from COVID-19
Professor Andy Ustianowski, Principal Clinical Research Lead, North Manchester General Hospital - View Bio
1320
Innovative design of clinical trials
Professor Sarah Walker, University College London - View Bio
1335
Developing a TB drug in academia: The BTZ043 from lead candidate to pivotal clinical trials – lesson learned from a complex endeavour
Professor Dr Michael Hoelscher, Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich
1350
Q&A
All speakers
SESSION SIX: Non-traditional approaches and challenges
Chair: Dr Ursula Theuretzbacher, Founder, Center for Anti-Infective Agents (CEFAIA) - View Bio
-
View Session Six here. This video consists of the following presentations:
1410
The non-traditional treatment pipeline
Dr Ursula Theuretzbacher, Founder, Center for Anti-Infective Agents (CEFAIA) - View Bio
1425
Elastase inhibitor
Dr Martin Everett, Chief Scientific Officer, Antabio - View Bio
1440
Therapeutic Development of Bacteriophages
Professor Martha Clokie, Professor of Microbiology, University of Leicester - View Bio
1455
Q&A
All speakers
SESSION SEVEN: KEYNOTE PRESENTATION
Chair: Dr Jean-Pierre Paccaud, Director, Business Development and Corporate Strategy, Global Antibiotic R&D Partnership (GARDP) - View Bio
-
View Session Seven here. This video consists of the following presentations:
1515
Facilitators and barriers to securing access to new and old antibiotics
Dr Christine Ardal, Senior Advisor, Institute of Public Health, Norway - View Bio
1535
Q&A
SESSION EIGHT: PANEL DISCUSSION
Chair: Professor Laura JV Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP) - View Bio
-
View Session Eight here. This video consists of the following presentations:
1555-1700
Careers in Drug Development and Antimicrobial Chemotherapy
Dr Olga Genilloud, Scientific Director, Fundación MEDINA - View Bio
Dr Sumathi Nambiar, Director, Division of Anti-Infective (DAI), FDA - View Bio
Prof Dr Rolf Müller, Head of Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) & Department Microbial Natural Products (MINS), Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) - View Bio
Dr Martin Everett, Chief Scientific Officer, Antabio - View Bio
1700
Closing remarks
Professor Laura Piddock, Director of Scientific Affairs, GARDP - View Bio
Abstracts
Please note that abstract submissions for this virtual conference has now closed.
Registration
Registration for this virtual conference has now closed.
